LARGO, Fla. / Mar 22, 2023 / Business Wire / CONMED Corporation (NYSE: CNMD) today announced that its Annual Meeting of Stockholders will be held on Wednesday, May 24, 2023, at 1:30 p.m. ET at its corporate headquarters at 11311 Concept Boulevard, Largo FL and through the internet virtually. Shareholders of record at the close of business on March 28, 2023 shall be entitled to vote at the 2023 Annual Meeting.
Information about the meeting webcast and instructions for how stockholders can attend or otherwise participate in the Annual Meeting will be included in the definitive proxy statement expected to be filed with the Securities and Exchange Commission on April 11, 2023 and available on the “Investors” section of CONMED’s web site at www.conmed.com on that date.
About CONMED Corporation
CONMED is a medical technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com.
Forward-Looking Statements
This press release may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to, the risks posed to the Company’s business, financial condition, and results of operations by the COVID-19 global pandemic and the various government and other responses to the pandemic, including deferral of surgeries, reductions in hospital and ambulatory surgery center operating volumes, disruption to potential supply chain reliability, as well as the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2022 and listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.
Last Trade: | US$49.44 |
Daily Change: | -1.54 -3.02 |
Daily Volume: | 69,078 |
Market Cap: | US$1.530B |
February 25, 2025 February 05, 2025 January 02, 2025 October 30, 2024 October 30, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load